Biomedical engineers at Georgia Tech created a treatment that could one day unlock a universal strategy for treating some of ...

Giving scientists direct control over DNA and mRNA synthesis timelines ... of cutting-edge solutions for health and technology. These breakthroughs in synthetic biology could help accelerate ...

Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced exciting preliminary Phase 1 ...

Here, the synthetic mRNA encoding tumour-associated ... Despite these challenges, mRNA technology can be used to express large and complex proteins that are difficult or impossible to generate ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the ...

Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, ...

The Board of 4basebio plc is pleased to report the results for the financial year ended 31 December 2024. The annual report and accounts together with a notice of the Company’s annual general meeting, ...

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to enable fully-enzymatic, overnight, on-site ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), ...